4篇
您的检索式：作者名="Stefano Calvieri"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastrointestinal and Retroperitoneal Manifestations of Type 1 Neurofibromatosis显示文摘 | Ursula Basile Giuseppe Cavallaro Andrea Polistena Sandra Giustini Gennaro Orlando Dario Cotesta Luigi Petramala Claudio Letizia Stefano Calvieri Giorgio Toma | 2010 | Journal of Gastrointestinal Surgery2010，，1： | 1 |
| 2 | Surgical Management of Abdominal Manifestations of Type 1 Neurofibromatosis: Experience of a Single Center显示文摘 | Cavallaro Giuseppe Basile Ursula Polistena Andrea Giustini Sandra Arena Rossella Scorsi Alessandro Zinnamosca Laura Letizia Claudio Calvieri Stefano De Toma Giorgio | 2010 | The American Surgeon2010，，4： | 1 |
| 3 | Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C显示文摘Up to date,in literature,it is still debated the role of anti-tumor necrosis factors(TNF)-α treatments in hepatitis C virus(HCV) patients.TNF-α performs a lot of functions,it is an important pro-inflammatory cytokine and it is involved in the host's immunity.Since TNF-α is implicated in the apoptotic signaling pathway of hepatocytes infected by HCV,anti TNF-α therapy may increase the risk of viral replication or their reactivation.However the treatment of anti TNF-α could have a healthful role because TNF-α appears to be engaged in the pathogenesis of liver fibrosis,inducing apoptotic pathways.We describe the case of a patient with plaquetype psoriasis and concomitant chronic HCV,who was treated successfully with anti-TNF agents simultaneously to cyclosporine without sign of reactivation of HCV and increase of liver enzymes.Our personal experience shows that anti-TNF-α agents are not only effective but also safe.Furthermore the combination therapy of cyclosporine and anti-TNF-α appears to be well-tolerated and able to reduce the amount of liver enzymes as well as HCV-viral-load.However systematic,large-scale studies with long follow-ups will be needed to confirm our results,in association with close liver function monitoring. | Monica Salvi Laura Macaluso Cecilia Luci Carlo Mattozzi Giovanni Paolino Yvonne Aprea Stefano Calvieri Antonio Giovanni Richetta | 2016 | World Journal of Clinical Cases2016，4，2： | 1 |
| 4 | 3D Non-Fluoroscopic Cryoablation of Right-Sided Accessory Pathways in Children:Monocentric Study and Literature Review显示文摘Background:Cryoablation of accessory pathways(APs)is effective and very safe in children,as previously reported by our group.The aim of this retrospective study was to evaluate the current efficacy of 3D non-fluoroscopic cryoablation of right sided APs in children,comparing results obtained with the Ensite VelocityTM and the more recent Ensite PrecisionTM 3D mapping systems.Methods and Results:From January 2016 to December 2019,102 pediatric patients[mean age 12.5±2.8,62 males(61%of total cohort)]with right APs underwent 3D non-fluoroscopic transcatheter cryoablation at our Institution.Fifteen(14.7%)patients had previously undergone catheter ablation.Acute procedural success rate was 95.1%(n=97).No significant differences were detected in acute success rates achieved with Ensite Velocity^(TM)or Ensite PrecisionTM systems nor between manifest(94%)and concealed APs(100%).No permanent complications occurred.During follow-up(428±286 days,median 396 days[interquartile range 179-713]),19 patients(19.6%)had recurrences.Recurrences were more frequent for parahissian/anterior APs compared to midseptal/posterior and lateral APs(p=0.043).Recurrences were not related to the Ensite system used.A redo ablation procedure was attempted in 13 cases,11 cryoablation and 2 radiofrequency ablations:the former was successful in 10 cases out of 11(90.9%).Conclusion:3D cryoablation of right-sided APs is associated with a very high acute success rate with limited use of fluoroscopy,resulting in great benefit to the children.Recurrence rates are not high and patients can be retreated with cryo-energy with higher success rates. | Fabrizio Drago Irma Battipaglia Pietro Paolo Tamborrino Luigina Porco Camilla Calvieri Mario Salvatore Russo Vincenzo Pazzano Romolo Remoli Massimo Stefano Silvetti | 2021 | Congenital Heart Disease2021，16，6： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员